🇺🇸 FDA
Pipeline program

BAY 3283142, BAY 3283142 PLACEBO, BAY 3283142, BAY 3283142

22040

Phase 2 small_molecule active

Quick answer

BAY 3283142, BAY 3283142 PLACEBO, BAY 3283142, BAY 3283142 for Chronic kidney disease is a Phase 2 program (small_molecule) at Bayer AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bayer AG
Indication
Chronic kidney disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials